CRNX

NEUTRALM&A

Crinetics Pharmaceuticals, Inc.

2026-08-21

Price

$84.69

+0.00%

This is the 2026-08-21 snapshot — the signals and analysis for CRNX as of this single trading day.

View full CRNX research hub →

Score10.5Top Tier

Signals7/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

Crinetics Pharmaceuticals (CRNX) is currently trading as a pure merger arbitrage play following Vertex Pharmaceuticals' definitive agreement to acquire the company for $85.00 per share in cash. The technical signals of SURGE, QUIET_STORM, and STEADY_CLIMB, combined with an ultra-low 2.4% annualized volatility, perfectly reflect this dynamic as the stock is pinned tightly just below the buyout price. While the broader RISK_ON macro regime and abundant liquidity provide a highly supportive environment for M&A activity to clear, CRNX's price action is now entirely tethered to the successful closure of the deal expected in Q3 2026.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUEBARGAIN HUNTER

Key Takeaways

Actionable Thesis: CRNX is a definitive merger arbitrage vehicle trading at $84.69, offering a fractional spread to the $85.00 cash acquisition price by Vertex Pharmaceuticals.
Key Risk: The primary risk is a 'deal break' due to unforeseen anti-trust regulatory hurdles, which would cause a severe downside reversion to pre-acquisition price levels.
What to Watch: Monitor for final administrative clearances and the official closing announcement expected in Q3 2026, which will finalize the payout.

← Back to 2026-08-21 View Full CRNX History →Yahoo Finance &nearr;